دورية أكاديمية

Safety of chemotherapy of MDR/XDR-TB patients in high HIV prevalence settings

التفاصيل البيبلوغرافية
العنوان: Safety of chemotherapy of MDR/XDR-TB patients in high HIV prevalence settings
المؤلفون: A. V. Kukurika, E. I. Veselova, L. E. Parolina, O. V. Lovacheva
المصدر: Туберкулез и болезни лёгких, Vol 100, Iss 11, Pp 56-65 (2022)
بيانات النشر: New Terra Publishing House, 2022.
سنة النشر: 2022
المجموعة: LCC:Diseases of the respiratory system
مصطلحات موضوعية: млу/шлу-тб, вич, безопасность, нежелательные побочные реакции, противотуберкулезные препараты, антиретровирусная терапия, схемы лечения, Diseases of the respiratory system, RC705-779
الوصف: The review used 61 literature sources to discuss 13 publications devoted to safety of treatment of HIV-associated drug-resistant tuberculosis using basic and new regimens of chemotherapy. According to the literature, no additive toxic effects were detected during treatment with anti-tuberculosis and antiretroviral drugs. According to the literature data, no additive toxic effect was found during treatment with anti-tuberculosis and antiretroviral drugs. In conditions of high prevalence of HIV, the pharmacovigilance of drug interactions in combination therapy is particularly relevant since HIV can indirectly increase the number of ADRs not only due to cross-toxicity but also severe immunosuppression, development of immune system recovery syndrome, opportunistic infections, a characteristic intoxication syndrome, a low index body weight and individual characteristics of patients in this category.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: Russian
تدمد: 2075-1230
2542-1506
Relation: https://www.tibl-journal.com/jour/article/view/1693; https://doaj.org/toc/2075-1230; https://doaj.org/toc/2542-1506
DOI: 10.21292/2075-1230-2022-100-11-56-65
URL الوصول: https://doaj.org/article/bcd7ea4f83d648b29700ac5bbd76a89e
رقم الأكسشن: edsdoj.bcd7ea4f83d648b29700ac5bbd76a89e
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:20751230
25421506
DOI:10.21292/2075-1230-2022-100-11-56-65